Literature DB >> 30006928

The power of the Mediator complex-Expanding the genetic architecture and phenotypic spectrum of MED12-related disorders.

A Charzewska1, R Maiwald2, K Kahrizi3, B Oehl-Jaschkowitz4, A Dufke5, J R Lemke5,6, H Enders5,7, H Najmabadi3, A Tzschach5,8, W Hachmann9, C Jensen10,11, M Bienek10, J Poznański12, M Nawara1, T Chilarska13, E Obersztyn1, D Hoffman-Zacharska1, M Gos1, J Bal1, V M Kalscheuer14.   

Abstract

MED12 is a member of the large Mediator complex that controls cell growth, development, and differentiation. Mutations in MED12 disrupt neuronal gene expression and lead to at least three distinct X-linked intellectual disability syndromes (FG, Lujan-Fryns, and Ohdo). Here, we describe six families with missense variants in MED12 (p.(Arg815Gln), p.(Val954Gly), p.(Glu1091Lys), p.(Arg1295Cys), p.(Pro1371Ser), and p.(Arg1148His), the latter being first reported in affected females) associated with a continuum of symptoms rather than distinct syndromes. The variants expanded the genetic architecture and phenotypic spectrum of MED12-related disorders. New clinical symptoms included brachycephaly, anteverted nares, bulbous nasal tip, prognathism, deep set eyes, and single palmar crease. We showed that MED12 variants, initially implicated in X-linked recessive disorders in males, may predict a potential risk for phenotypic expression in females, with no correlation of the X chromosome inactivation pattern in blood cells. Molecular modeling (Yasara Structure) performed to model the functional effects of the variants strongly supported the pathogenic character of the variants examined. We showed that molecular modeling is a useful method for in silico testing of the potential functional effects of MED12 variants and thus can be a valuable addition to the interpretation of the clinical and genetic findings.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  FG syndrome; Lujan-Fryns syndrome; MED12; Ohdo syndrome; X-linked intellectual disability; molecular modeling

Mesh:

Substances:

Year:  2018        PMID: 30006928     DOI: 10.1111/cge.13412

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  6 in total

Review 1.  MED12-Related (Neuro)Developmental Disorders: A Question of Causality.

Authors:  Stijn van de Plassche; Arjan Pm de Brouwer
Journal:  Genes (Basel)       Date:  2021-04-28       Impact factor: 4.096

2.  Dysregulations of sonic hedgehog signaling in MED12-related X-linked intellectual disability disorders.

Authors:  Siddharth Srivastava; Tejasvi Niranjan; Melanie M May; Patrick Tarpey; William Allen; Anna Hackett; Pierre-Simon Jouk; Lucy Raymond; Slyvain Briault; Cindy Skinner; Annick Toutain; Jozef Gecz; William Heath; Roger E Stevenson; Charles E Schwartz; Tao Wang
Journal:  Mol Genet Genomic Med       Date:  2019-02-06       Impact factor: 2.183

3.  A novel nonsense variant in MED12 associated with malformations in a female fetus.

Authors:  Soren Lejsted Faergeman; Naja Becher; Lotte Andreasen; Marianne Christiansen; Lise Frost; Ida Vogel
Journal:  Clin Case Rep       Date:  2021-12-22

4.  MED12-related Hardikar syndrome: Two additional cases and novel phenotypic features.

Authors:  Nishitha R Pillai; Dana Miller; Grace Bronken; Amrita Kahlon Salunke; Anjali Aggarwal
Journal:  Am J Med Genet A       Date:  2022-04-06       Impact factor: 2.578

5.  Targeted Next-Generation Sequencing in Patients with Suggestive X-Linked Intellectual Disability.

Authors:  Nekane Ibarluzea; Ana Belén de la Hoz; Olatz Villate; Isabel Llano; Intzane Ocio; Itxaso Martí; Miriam Guitart; Elisabeth Gabau; Fernando Andrade; Blanca Gener; María-Isabel Tejada
Journal:  Genes (Basel)       Date:  2020-01-02       Impact factor: 4.096

6.  MED12 Mutation in Two Families with X-Linked Ohdo Syndrome.

Authors:  Luca Rocchetti; Eloisa Evangelista; Luigia De Falco; Giovanni Savarese; Pasquale Savarese; Raffaella Ruggiero; Luigi D'Amore; Alberto Sensi; Antonio Fico
Journal:  Genes (Basel)       Date:  2021-08-27       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.